Professional
Added to YB: 2024-09-10
Pitch date: 2024-06-30
CABA [bullish]
Cabaletta Bio, Inc.
-68.19%
current return
Author Info
No bio for this author
Company Info
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Market Cap
$230.1M
Pitch Price
$7.42
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.61
P/E
-0.99
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Alger Small Cap Focus Fund Porfolio Holding - Cabaletta Bio, Inc.
CABA: Clinical-stage biotech developing CAR-T for autoimmune diseases. Stock down on biotech sector weakness, high rates, antibody drug competition, CAR-T durability concerns. Multibillion-dollar opportunity, first-mover advantage. Upcoming trial data to show efficacy, safety, durability.
Read full article (1 min)